https://scutellarininhibitor.c....om/development-assoc
The present study aimed to develop the novel lipid base formulations to a target and inhibit the mobile proliferation of Her-2-expressing cancer of the breast cells through the silencing of FASN. In order to achieve this objective, we prepared DSPC/Chol and DOPE/CHEMS immunoliposomes, conjugated because of the anti-Her-2 fab' and encapsulated FASN siRNA against breast cancer tumors cells. The data disclosed that both nanosized FASN-siRNA-encapsulated
Me gusta
Comentario
Compartir
